Abstract OT2-22-02: Sequencing of anthracyclines and taxanes during neoadjuvant therapy of locally advanced HER2-negative breast cancer (NEOSAMBA Study/LACOG 0419)

01/03/2023

Tomás Reinert; Cristiano P. Souza; Pedro Liedke; Gustavo Werutsky; Laura Testa; Vivian Antunes; Carlos Barrios; Vivian Vasconcelos; Heloísa Resende; Geraldo Silva Queiroz; Gisah Guilgen; Yeni Nerón; Lilian Arruda Bastos; Sabina Aleixo; Daniel Cubero; Maria Cristina F. Magalhães; Ana Coradazzi; Daniela Galvão B. de Oliveira; João S. Nunes; Rafaela G. Jesus; Gustavo Gössling; José Bines

DOI: 10.1158/1538-7445.SABCS22-OT2-22-02

Full link: https://aacrjournals.org/cancerres/article/83/5_Supplement/OT2-22-02/717960/Abstract-OT2-22-02-Sequencing-of-anthracyclines

Abstract OT2-22-02: Sequencing of anthracyclines and taxanes during neoadjuvant therapy of locally advanced HER2-negative breast cancer (NEOSAMBA Study/LACOG 0419)

Send us a message

Cura Project

Abstract OT2-22-02: Sequencing of anthracyclines and taxanes during neoadjuvant therapy of locally advanced HER2-negative breast cancer (NEOSAMBA Study/LACOG 0419)

Related Posts

1506TiP A single-arm, phase II study of amivantamab (AMI), lazertinib (L) and pemetrexed (P) for first-line treatment of recurrent/metastatic non-small cell lung cancers (NSCLCS) with epidermal growth factor receptor mutations in Exons 19 or 21 (EGFR 19/21): AMIGO 1 (LACOG0821)

Real-world evidence for oncological outcomes after radiotherapy or surgery for T1a-T1b glottic squamous cell carcinoma: A population-based cohort study

Clinical validation and diagnostic accuracy of 99mTc-EDDA/HYNIC-TOC compared to 111In-DTPA-octreotide in patients with neuroendocrine tumours: the LACOG 0214 study

Radiotherapy combined or not with chemotherapy in adult or pedriatic patients with brainstem glioma: a population-bases study